Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease. While non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) have contributed to management, it was not until the advent of biologics (and later on targeted synthetic DMARDs) that therapy was revolutionized, with the achievement of significantly better clinical and radiographic outcomes. Several drugs and treatment approaches are currently being tested in clinical trials at different phases. Despite all the success, there are still various challenges and unmet needs in the field of PsA, reflected by difficult-to-treat disease course, secondary failure of therapy, and lack of consensus on accepted treatment withdrawal protocols, among others. In this mini-review, we have discussed the most recent advances in the therapy of psoriatic disease, with a particular focus on phase III studies completed (or ongoing) since 2020. We also mentioned the challenges and unmet needs in our clinical practice, which we expect current and future research to provide answers to.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971339350240830104424
2025-01-01
2025-11-28

  • From This Site

    /content/journals/crr/10.2174/0115733971339350240830104424
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CoatesL.C. HelliwellP.S. Psoriatic arthritis: state of the art review.Clin. Med. (Lond.)2017171657010.7861/clinmedicine.17‑1‑6528148584
     [Google Scholar]
  2. CoatesL.C. SorianoE.R. CorpN. BertheussenH. Callis DuffinK. CampanholoC.B. ChauJ. EderL. Fernández-ÁvilaD.G. FitzGeraldO. GargA. GladmanD.D. GoelN. HelliwellP.S. HusniM.E. JadonD.R. KatzA. LaheruD. LatellaJ. LeungY.Y. LindsayC. LubranoE. MazzuoccoloL.D. MeaseP.J. O’SullivanD. OgdieA. OlsderW. PalominosP.E. SchickL. SteinkoenigI. de WitM. van der WindtD.A. KavanaughA. CampanholoC. FitzgeraldO. GladmanD. HelliwellP. HusniM.E. LaheruD. LeungY-Y. LubranoE. MazzuoccoloL.D. MeaseP.J. OgdieA. PalominosP.E. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.Nat. Rev. Rheumatol.202218846547910.1038/s41584‑022‑00798‑035761070
     [Google Scholar]
  3. HusniM.E. Comorbidities in Psoriatic Arthritis.Rheum. Dis. Clin. North Am.201541467769810.1016/j.rdc.2015.07.00826476226
     [Google Scholar]
  4. RitchlinC.T. ColbertR.A. GladmanD.D. Psoriatic Arthritis.N Engl J Med.20173761095797010.1056/NEJMra1505557
     [Google Scholar]
  5. EderL. GladmanD.D. Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?Expert Rev. Clin. Immunol.201410676377010.1586/1744666X.2014.90574124702706
     [Google Scholar]
  6. CuéllarM.L. CiteraG. EspinozaL.R. Treatment of psoriatic arthritis.Baillieres Clin. Rheumatol.19948248349810.1016/S0950‑3579(94)80030‑88076399
     [Google Scholar]
  7. MerolaJ.F. LockshinB. ModyE.A. Switching biologics in the treatment of psoriatic arthritis.Semin. Arthritis Rheum.2017471293710.1016/j.semarthrit.2017.02.00128363434
     [Google Scholar]
  8. RidaM.A. LeeK.A. ChandranV. CookR.J. GladmanD.D. Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort.Arthritis Care Res. (Hoboken)202375102174218110.1002/acr.2511236913183
     [Google Scholar]
  9. BarnasJ.L. RitchlinC.T. Etiology and pathogenesis of psoriatic arthritis.Rheum. Dis. Clin. North Am.201541464366310.1016/j.rdc.2015.07.00626476224
     [Google Scholar]
  10. VecellioM. HakeV.X. DavidsonC. CarenaM.C. WordsworthB.P. SelmiC. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis.Front. Immunol.20211159608610.3389/fimmu.2020.59608633574815
     [Google Scholar]
  11. CrispinoN. CicciaF. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis.Clin. Exp. Rheumatol.202139366867510.55563/clinexprheumatol/e7ayu833200731
     [Google Scholar]
  12. TravesP.G. MurrayB. CampigottoF. GalienR. MengA. Di PaoloJ.A. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.Ann. Rheum. Dis.202180786587510.1136/annrheumdis‑2020‑21901233741556
     [Google Scholar]
  13. McInnesI.B. KavanaughA. GottliebA.B. PuigL. RahmanP. RitchlinC. BrodmerkelC. LiS. WangY. MendelsohnA.M. DoyleM.K. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.Lancet2013382989478078910.1016/S0140‑6736(13)60594‑223769296
     [Google Scholar]
  14. RitchlinC. RahmanP. KavanaughA. McInnesI.B. PuigL. LiS. WangY. ShenY.K. DoyleM.K. MendelsohnA.M. GottliebA.B. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6- month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.Ann. Rheum. Dis.201473699099910.1136/annrheumdis‑2013‑20465524482301
     [Google Scholar]
  15. DeodharA. HelliwellP.S. BoehnckeW.H. KollmeierA.P. HsiaE.C. SubramanianR.A. XuX.L. ShengS. AgarwalP. ZhouB. ZhuangY. RitchlinC.T. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet2020395102301115112510.1016/S0140‑6736(20)30265‑832178765
     [Google Scholar]
  16. MeaseP.J. RahmanP. GottliebA.B. KollmeierA.P. HsiaE.C. XuX.L. ShengS. AgarwalP. ZhouB. ZhuangY. van der HeijdeD. McInnesI.B. Guselkumab in biologic- naive patients with active psoriatic arthritis (discover-2): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet2020395102301126113610.1016/S0140‑6736(20)30263‑432178766
     [Google Scholar]
  17. CoatesL.C. RitchlinC.T. GossecL. HelliwellP.S. RahmanP. KollmeierA.P. XuX.L. ShawiM. KaryekarC.S. ContréC. NoëlW. ShengS. WangY. XuS. MeaseP.J. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.Rheumatology (Oxford)202362260661610.1093/rheumatology/keac37535766811
     [Google Scholar]
  18. CoatesL.C. GossecL. TheanderE. BergmansP. NeuholdM. KaryekarC.S. ShawiM. NoëlW. SchettG. McInnesI.B. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).Ann. Rheum. Dis.202281335936910.1136/annrheumdis‑2021‑22099134819273
     [Google Scholar]
  19. SchettG. ChenW. GaoS. ChakravartyS.D. ShawiM. LavieF. ZimmermannM. SharafM. CoatesL.C. SiebertS. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.Arthritis Res. Ther.202325115010.1186/s13075‑023‑03125‑437587493
     [Google Scholar]
  20. RitchlinC.T. CoatesL.C. MeaseP.J. van der HeijdeD. SongJ. JiangY. ShawiM. KollmeierA.P. RahmanP. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.Trials20232412210.1186/s13063‑022‑06945‑y36627711
     [Google Scholar]
  21. GladmanD.D. MeaseP.J. BirdP. SorianoE.R. ChakravartyS.D. ShawiM. XuS. QuinnS.T. GongC. LeibowitzE. PoddubnyyD. TamL.S. HelliwellP.S. KavanaughA. DeodharA. ØstergaardM. BaraliakosX. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.Trials202223174310.1186/s13063‑022‑06589‑y36064592
     [Google Scholar]
  22. BlairH.A. Risankizumab: a review in moderate to severe plaque psoriasis.Drugs202080121235124510.1007/s40265‑020‑01357‑132632826
     [Google Scholar]
  23. KristensenL.E. KeisermanM. PappK. McCaslandL. WhiteD. LuW. WangZ. SolimanA.M. EldredA. BarcombL. BehrensF. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.Ann. Rheum. Dis.202281222523110.1136/annrheumdis‑2021‑22101934911706
     [Google Scholar]
  24. ÖstörA. Van den BoschF. PappK. AsnalC. BlancoR. AelionJ. AlperovichG. LuW. WangZ. SolimanA.M. EldredA. BarcombL. KivitzA. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.Ann. Rheum. Dis.202281335135810.1136/annrheumdis‑2021‑22104834815219
     [Google Scholar]
  25. ReichK. PappK.A. BlauveltA. TyringS.K. SinclairR. ThaçiD. NogralesK. MehtaA. CichanowitzN. LiQ. LiuK. La RosaC. GreenS. KimballA.B. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (resurface 1 and resurface 2): results from two randomised controlled, phase 3 trials.Lancet20173901009127628810.1016/S0140‑6736(17)31279‑528596043
     [Google Scholar]
  26. MeaseP.J. ChohanS. FructuosoF.J.G. LuggenM.E. RahmanP. RaychaudhuriS.P. ChouR.C. MendelsohnA.M. RozzoS.J. GottliebA. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.Ann. Rheum. Dis.20218091147115710.1136/annrheumdis‑2020‑21901433985942
     [Google Scholar]
  27. GossecL. KerschbaumerA. FerreiraR.J.O. AletahaD. BaraliakosX. BertheussenH. BoehnckeW.H. EsbensenB.A. McInnesI.B. McGonagleD. WinthropK.L. BalanescuA. BalintP.V. BurmesterG.R. CañeteJ.D. ClaudepierreP. EderL. HetlandM.L. IagnoccoA. KristensenL.E. LoriesR. QueiroR. MauroD. Marzo-OrtegaH. MeaseP.J. NashP. WagenaarW. SavageL. SchettG. Shoop-WorrallS.J.W. TanakaY. Van den BoschF.E. van der Helm-van MilA. ZabottiA. van der HeijdeD. SmolenJ.S. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.Ann. Rheum. Dis.2024836ard-2024-22553110.1136/ard‑2024‑22553138499325
     [Google Scholar]
  28. Araujoe.g. EnglbrechtM. HoepkenS. FinzelS. KampylafkaE. KleyerA. BayatS. SchoenauV. HueberA. RechJ. SchettG. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.Semin. Arthritis Rheum.201948463263710.1016/j.semarthrit.2018.05.01130037432
     [Google Scholar]
  29. YangK. OakA.S.W. ElewskiB.E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review.Am. J. Clin. Dermatol.202122217319210.1007/s40257‑020‑00578‑033301128
     [Google Scholar]
  30. BlauveltA. PappK.A. GriffithsC.E.M. RandazzoB. WasfiY. ShenY.K. LiS. KimballA.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial.J. Am. Acad. Dermatol.201776340541710.1016/j.jaad.2016.11.04128057360
     [Google Scholar]
  31. ReichK. ArmstrongA.W. FoleyP. SongM. WasfiY. RandazzoB. LiS. ShenY.K. GordonK.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial.J. Am. Acad. Dermatol.201776341843110.1016/j.jaad.2016.11.04228057361
     [Google Scholar]
  32. ReichK. GooderhamM. ThaçiD. CrowleyJ.J. RyanC. KruegerJ.G. TsaiT.F. FlackM. GuY. WilliamsD.A. ThompsonE.H.Z. PaulC. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial.Lancet20193941019857658610.1016/S0140‑6736(19)30952‑331280967
     [Google Scholar]
  33. PoddubnyyD. Managing psoriatic arthritis patients presenting with axial symptoms.Drugs202383649750510.1007/s40265‑023‑01857‑w36976477
     [Google Scholar]
  34. BaetenD. ØstergaardM. WeiJ.C.C. SieperJ. JärvinenP. TamL.S. SalvaraniC. KimT.H. SolingerA. DatsenkoY. PamulapatiC. VisvanathanS. HallD.B. AslanyanS. SchollP. PadulaS.J. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.Ann. Rheum. Dis.20187791295130210.1136/annrheumdis‑2018‑21332829945918
     [Google Scholar]
  35. DeodharA. GenslerL.S. SieperJ. ClarkM. CalderonC. WangY. ZhouY. LeuJ.H. CampbellK. SweetK. HarrisonD.D. HsiaE.C. van der HeijdeD. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.Arthritis Rheumatol.201971225827010.1002/art.4072830225992
     [Google Scholar]
  36. KavanaughA. PuigL. GottliebA.B. RitchlinC. YouY. LiS. SongM. RandazzoB. RahmanP. McInnesI.B. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).Ann. Rheum. Dis.201675111984198810.1136/annrheumdis‑2015‑20906827098404
     [Google Scholar]
  37. MeaseP.J. HelliwellP.S. GladmanD.D. PoddubnyyD. BaraliakosX. ChakravartyS.D. KollmeierA.P. HsiaE.C. XuX.L. ShengS. AgarwalP. ZhouB. SweetK. ShawiM. KaryekarC.S. DeodharA. van der HeijdeD. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.Lancet Rheumatol.2021310e715e72310.1016/S2665‑9913(21)00105‑338287608
     [Google Scholar]
  38. BraunJ. LandewéR.B.M. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?Ann. Rheum. Dis.202281446646810.1136/annrheumdis‑2021‑22142234656991
     [Google Scholar]
  39. PoddubnyyD BaraliakosX Van Den BoschF BraunJ CoatesLC ChandranV Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).Ther Adv Musculoskelet Dis.2021131759720X2110579
     [Google Scholar]
  40. RuggieroA. PotestioL. CamelaE.Snr FabbrociniG. MegnaM. Bimekizumab for the treatment of psoriasis: a review of the current knowledge.Psoriasis (Auckl.)20221212713710.2147/PTT.S36774435707807
     [Google Scholar]
  41. McInnesI.B. AsahinaA. CoatesL.C. LandewéR. MerolaJ.F. RitchlinC.T. TanakaY. GossecL. GottliebA.B. WarrenR.B. InkB. AssudaniD. BajracharyaR. ShendeV. CoarseJ. MeaseP.J. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).Lancet202340110370253710.1016/S0140‑6736(22)02302‑936493791
     [Google Scholar]
  42. MerolaJ.F. LandewéR. McInnesI.B. MeaseP.J. RitchlinC.T. TanakaY. AsahinaA. BehrensF. GladmanD.D. GossecL. GottliebA.B. ThaçiD. WarrenR.B. InkB. AssudaniD. BajracharyaR. ShendeV. CoarseJ. CoatesL.C. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).Lancet202340110370384810.1016/S0140‑6736(22)02303‑036495881
     [Google Scholar]
  43. CoatesL.C. McInnesI.B. MerolaJ.F. WarrenR.B. KavanaughA. GottliebA.B. GossecL. AssudaniD. BajracharyaR. CoarseJ. InkB. RitchlinC.T. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open-label extension study.Arthritis Rheumatol.202274121959197010.1002/art.4228035829656
     [Google Scholar]
  44. MeaseP.J. SmolenJ.S. BehrensF. NashP. Liu LeageS. LiL. TahirH. GooderhamM. KrishnanE. Liu-SeifertH. EmeryP. PillaiS.G. HelliwellP.S. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.Ann. Rheum. Dis.202079112313110.1136/annrheumdis‑2019‑21538631563894
     [Google Scholar]
  45. McInnesI.B. BehrensF. MeaseP.J. KavanaughA. RitchlinC. NashP. MasmitjaJ.G. GoupilleP. KorotaevaT. GottliebA.B. MartinR. DingK. PelletP. MpofuS. PricopL. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (Exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.Lancet2020395102351496150510.1016/S0140‑6736(20)30564‑X32386593
     [Google Scholar]
  46. WarrenR.B. BlauveltA. BagelJ. PappK.A. YamauchiP. ArmstrongA. LangleyR.G. VanvoordenV. De CuyperD. CioffiC. PetersonL. CrossN. ReichK. Bimekizumab versus Adalimumab in Plaque Psoriasis.N. Engl. J. Med.2021385213014110.1056/NEJMoa210238833891379
     [Google Scholar]
  47. BlauveltA. ReichK. TsaiT.F. TyringS. VanaclochaF. KingoK. ZivM. PinterA. VenderR. HugotS. YouR. MilutinovicM. ThaçiD. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.J. Am. Acad. Dermatol.20177616069.e910.1016/j.jaad.2016.08.00827663079
     [Google Scholar]
  48. ReichK. PinterA. LacourJ.P. FerrandizC. MicaliG. FrenchL.E. LomagaM. DutroncY. HennegesC. WilhelmS. HartzS. PaulC. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.Br. J. Dermatol.201717741014102310.1111/bjd.1566628542874
     [Google Scholar]
  49. ReichK. PappK.A. BlauveltA. LangleyR.G. ArmstrongA. WarrenR.B. GordonK.B. MerolaJ.F. OkuboY. MaddenC. WangM. CioffiC. VanvoordenV. LebwohlM. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.Lancet20213971027348749810.1016/S0140‑6736(21)00125‑233549193
     [Google Scholar]
  50. ThaçiD. BlauveltA. ReichK. TsaiT.F. VanaclochaF. KingoK. ZivM. PinterA. HugotS. YouR. MilutinovicM. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.J. Am. Acad. Dermatol.201573340040910.1016/j.jaad.2015.05.01326092291
     [Google Scholar]
  51. LebwohlM. StroberB. MenterA. GordonK. WeglowskaJ. PuigL. PappK. SpelmanL. TothD. KerdelF. ArmstrongA.W. StinglG. KimballA.B. BachelezH. WuJ.J. CrowleyJ. LangleyR.G. BlicharskiT. PaulC. LacourJ.P. TyringS. KircikL. ChimentiS. Callis DuffinK. BagelJ. KooJ. ArasG. LiJ. SongW. MilmontC.E. ShiY. EronduN. KlekotkaP. KotzinB. NirulaA. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.N. Engl. J. Med.2015373141318132810.1056/NEJMoa150382426422722
     [Google Scholar]
  52. ReichK. WarrenR.B. LebwohlM. GooderhamM. StroberB. LangleyR.G. PaulC. De CuyperD. VanvoordenV. MaddenC. CioffiC. PetersonL. BlauveltA. Bimekizumab versus Secukinumab in Plaque Psoriasis.N. Engl. J. Med.2021385214215210.1056/NEJMoa210238333891380
     [Google Scholar]
  53. ReichK. ArmstrongA.W. LangleyR.G. FlavinS. RandazzoB. LiS. HsuM.C. BraniganP. BlauveltA. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.Lancet20193941020183183910.1016/S0140‑6736(19)31773‑831402114
     [Google Scholar]
  54. BlauveltA. PappK. GottliebA. JarellA. ReichK. MaariC. GordonK.B. FerrisL.K. LangleyR.G. TadaY. LimaR.G. ElmaraghyH. GalloG. RendaL. ParkS.Y. BurgeR. BagelJ. VenderR. LomagaM.A. DelormeI. HongC-H. LangleyR.L. AlbrechtL. GuentherL. MaariC. PappK. Singh OhsonK.K. BarberK. LyndeC. GuptaA. RosophL. GauthierJ-S. GooderhamM. WaselN. RamanM. WisemanM. GreensteinD. JarellA. MoonC. ClarkL. JazayeriS.S. BukhaloM. MooreA. HamiltonT.K. GewirtzmanA. HazanL. CrowleyJ. TellerC. ZirwasM. SmithS.R. Christine LeeM. TyringS. LeeP. DhawanS. LeonardiC. JesusA.P-D. McFaldaW. FrankelE. YamauchiP. FretzinS. SerraoR. SchlesingerT. GottliebS. JenkinP. GharibR. DavisS. NamiN. DraelosZ.D. GodwinL. OwenC. LandisM. AbramovitsW. Sanchez-RiveraS. Van VoorheesA. FivensonD. KerdelF. FormanS.B. WeinbergJ. Gonzalez-ChavezJ. BoyceB. Stein-GoldL. HudsonC. BrownC. CoggiJ. FeserC. ForconiR. JohnsonS. McCuneM. GreenL. MadkanV. ShippD.M. GordonK. WaibelJ. Soto-RaicesO. CatherJ. MillerS. ScottJ. YoungD. KaffenbergerJ. YokumK. ZookM. BlauveltA. TruettA. SchmiederG. McCrackenG. McElgunnP. HerrmannJ. SuchniakJ.M. AppelJ. BarrancoE. LeeM. BagelJ. OsmanL. CauthenA. SadickN. De La TorreE. TaylorK. CohenD. HarrisH.H. SoungJ. DimitropoulosV. MillerS. BarnesC. Jumean-HaddadR. BruceS. CheungL. GuenthnerS. GaspariA. LaquerV. KrellJ.M. JacobsS. NahmW. KormanN. ElewskiB. FerrisL. DuffinK.C. PariserD. JohnsonB. WallaceP. TraversJ. FriedR. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.Br. J. Dermatol.202018261348135810.1111/bjd.1885131887225
     [Google Scholar]
  55. BlauveltA. LeonardiC. ElewskiB. CrowleyJ.J. GuentherL.C. GooderhamM. LangleyR.G. VenderR. PinterA. GriffithsC.E.M. TadaY. ElmaraghyH. LimaR.G. GalloG. RendaL. BurgeR. ParkS.Y. ZhuB. PappK. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.Br. J. Dermatol.202118461047105810.1111/bjd.1950932880909
     [Google Scholar]
  56. WarrenR.B. BlauveltA. PoulinY. BeeckS. KellyM. WuT. GengZ. PaulC. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial.Br. J. Dermatol.20211841505910.1111/bjd.1934132594522
     [Google Scholar]
  57. RamiroS. NikiphorouE. SeprianoA. OrtolanA. WebersC. BaraliakosX. LandewéR.B.M. Van den BoschF.E. BotevaB. BremanderA. CarronP. CiureaA. van GaalenF.A. GéherP. GenslerL. HermannJ. de HoogeM. HusakovaM. KiltzU. López-MedinaC. MachadoP.M. Marzo-OrtegaH. MoltoA. Navarro-CompánV. NissenM.J. Pimentel-SantosF.M. PoddubnyyD. ProftF. RudwaleitM. TelkmanM. ZhaoS.S. ZiadeN. van der HeijdeD. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.Ann. Rheum. Dis.2023821193410.1136/ard‑2022‑22329636270658
     [Google Scholar]
  58. BaraliakosX. GossecL. PournaraE. JekaS. Mera-VarelaA. D’AngeloS. SchulzB. RisslerM. NagarK. PerellaC. CoatesL.C. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.Ann. Rheum. Dis.202180558259010.1136/annrheumdis‑2020‑21880833334727
     [Google Scholar]
  59. DeodharA GladmanD BolceR SandovalD ParkSY LeageSL The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.Ther Adv Musculoskelet Dis.2023151759720X231189005
     [Google Scholar]
  60. McInnesI.B. AndersonJ.K. MagreyM. MerolaJ.F. LiuY. KishimotoM. JekaS. Pacheco-TenaC. WangX. ChenL. ZuegerP. LiuJ. PanganA.L. BehrensF. Trial of upadacitinib and adalimumab for psoriatic arthritis.N. Engl. J. Med.2021384131227123910.1056/NEJMoa202251633789011
     [Google Scholar]
  61. MeaseP.J. LertratanakulA. AndersonJ.K. PappK. Van den BoschF. TsujiS. DokoupilovaE. KeisermanM. WangX. ZhongS. McCaskillR.M. ZuegerP. PanganA.L. TillettW. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.Ann. Rheum. Dis.202180331232010.1136/annrheumdis‑2020‑21887033272960
     [Google Scholar]
  62. McInnesI.B. KatoK. MagreyM. MerolaJ.F. KishimotoM. Pacheco-TenaC. HaalandD. ChenL. DuanY. ZuegerP. LiuJ. LippeR. PanganA.L. BehrensF. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.RMD Open202173e00183810.1136/rmdopen‑2021‑00183834663636
     [Google Scholar]
  63. ArmstrongA.W. GooderhamM. WarrenR.B. PappK.A. StroberB. ThaçiD. MoritaA. SzepietowskiJ.C. ImafukuS. ColstonE. ThroupJ. KunduS. SchoenfeldS. LinaberryM. BanerjeeS. BlauveltA. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.J. Am. Acad. Dermatol.2023881293910.1016/j.jaad.2022.07.00235820547
     [Google Scholar]
  64. StroberB. ThaçiD. SofenH. KircikL. GordonK.B. FoleyP. RichP. PaulC. BagelJ. ColstonE. ThroupJ. KunduS. SekaranC. LinaberryM. BanerjeeS. PappK.A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.J. Am. Acad. Dermatol.2023881405110.1016/j.jaad.2022.08.06136115523
     [Google Scholar]
  65. MeaseP.J. DeodharA.A. van der HeijdeD. BehrensF. KivitzA.J. NealJ. KimJ. SinghalS. NowakM. BanerjeeS. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.Ann. Rheum. Dis.202281681582210.1136/annrheumdis‑2021‑22166435241426
     [Google Scholar]
  66. BerekmeriA. MahmoodF. WittmannM. HelliwellP. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.Expert Rev. Clin. Immunol.201814971973010.1080/1744666X.2018.151240430118353
     [Google Scholar]
  67. EdwardsC.J. BlancoF.J. CrowleyJ. BirbaraC.A. JaworskiJ. AelionJ. StevensR.M. VesseyA. ZhanX. BirdP. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).Ann. Rheum. Dis.20167561065107310.1136/annrheumdis‑2015‑20796326792812
     [Google Scholar]
  68. PappK. CatherJ.C. RosophL. SofenH. LangleyR.G. MathesonR.T. HuC. DayR.M. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.Lancet2012380984373874610.1016/S0140‑6736(12)60642‑422748702
     [Google Scholar]
  69. DeodharA. PoddubnyyD. Pacheco-TenaC. SalvaraniC. LespessaillesE. RahmanP. JärvinenP. Sanchez-BursonJ. GaffneyK. LeeE.B. KrishnanE. SantistebanS. LiX. ZhaoF. CarlierH. ReveilleJ.D. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors.Arthritis Rheumatol.201971459961110.1002/art.4075330343531
     [Google Scholar]
  70. van der HeijdeD. Cheng-Chung WeiJ. DougadosM. MeaseP. DeodharA. MaksymowychW.P. Van den BoschF. SieperJ. TomitaT. LandewéR. ZhaoF. KrishnanE. AdamsD.H. PangalloB. CarlierH. ChurchillM. FlintK. GladsteinG. GreenwaldM. HowellM. InceA. KaineJ. MehtaD. PetersE. QuerubinR. ReveilleJ. RoseffR. DiegelR. ThaiC. BessetteL. MorinF. RahmanP. Barrera RodriguezA.A. Cons-MolinaF. Duran BarraganS. SkinnerC. Pacheco TenaC. Ramos RemusC. Rizo RodriguezJ.C. HongS-J. LeeY-A. JuJ.H. KangS.W. KimT-H. LeeC.K. LeeE.B. LeeS.H. ParkM-C. ShinK. LeeS-H. ChenH-A. ChenY-C. HsiehS-C. LanJ-L. DvorakZ. MoravcovaR. MalcovaM. TaniguchiY. KishimotoM. TadaK. DobashiH. InuiK. UekiY. MatsumotoY. KoyamaY. HattaK. AtsumiT. GotoH. MatsuiK. TakakuboY. NeeckG. PoddubnyyD. Rubbert-RothA. SzymanskaM. BlicharskiT. DudekA. RacewiczA. WojciechowskiR. van de SandeM. GriepE. NurmohamedM. MatsievskayaG. ShmidtE. StanislavM. YakushinS. ErshovaO. RebrovA. BalazsT. CseuzR. DrescherE. PoorG. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.Lancet2018392101632441245110.1016/S0140‑6736(18)31946‑930360964
     [Google Scholar]
  71. DeodharA. Sliwinska-StanczykP. XuH. BaraliakosX. GenslerL.S. FleishakerD. WangL. WuJ. MenonS. WangC. DinaO. FallonL. KanikK.S. van der HeijdeD. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.Ann. Rheum. Dis.20218081004101310.1136/annrheumdis‑2020‑21960133906853
     [Google Scholar]
  72. van der HeijdeD. SongI.H. PanganA.L. DeodharA. van den BoschF. MaksymowychW.P. KimT.H. KishimotoM. EverdingA. SuiY. WangX. ChuA.D. SieperJ. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.Lancet2019394102142108211710.1016/S0140‑6736(19)32534‑631732180
     [Google Scholar]
  73. BaraliakosX. RanzaR. ÖstörA. CicciaF. CoatesL.C. RednicS. WalshJ.A. DouglasK. GaoT. KatoK. SongI.H. GanzF. DeodharA. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.Arthritis Res. Ther.20232515610.1186/s13075‑023‑03027‑537038159
     [Google Scholar]
  74. ProftF. TorgutalpM. MucheB. RiosR.V. VerbaM. PoddubnyyD. Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial.BMJ Open20211111e04864710.1136/bmjopen‑2021‑04864734785545
     [Google Scholar]
  75. HamiltonT.K. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.J. Drugs Dermatol.20087111089109319110745
     [Google Scholar]
  76. RathodD. WeinbergJ.M. YamauchiP.S. KircikL.H. WollinaU. LottiT. GoldustM. Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report.J. Drugs Dermatol.201918439439631017383
     [Google Scholar]
  77. HeineckeG.M. LuberA.J. LevittJ.O. LebwohlM.G. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.J. Drugs Dermatol.201312101098110224085044
     [Google Scholar]
  78. ThibodeauxQ. LyK. ReddyV. SmithM.P. LiaoW. Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.JAAD Case Rep.201951092893010.1016/j.jdcr.2019.08.01531649982
     [Google Scholar]
  79. CuchacovichR Garcia-ValladaresI EspinozaLR Combination biologic treatment of refractory psoriasis and psoriatic arthritis.J Rheumatol.2012391187193
     [Google Scholar]
  80. GenoveseM.C. CohenS. MorelandL. LiumD. RobbinsS. NewmarkR. BekkerP. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.Arthritis Rheum.20045051412141910.1002/art.2022115146410
     [Google Scholar]
  81. AlharbiS. YeJ.Y. LeeK.A. ChandranV. CookR.J. GladmanD.D. Remission in psoriatic arthritis: Definition and predictors.Semin. Arthritis Rheum.20205061494149910.1016/j.semarthrit.2020.01.01232145969
     [Google Scholar]
  82. CoatesL.C. CookR. LeeK.A. ChandranV. GladmanD.D. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort.Arthritis Care Res. (Hoboken)201062797097610.1002/acr.2016220191569
     [Google Scholar]
  83. YeW. TuckerL.J. CoatesL.C. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity.Drugs201878161705171510.1007/s40265‑018‑0994‑330341684
     [Google Scholar]
  84. HaddadA. ThavaneswaranA. Ruiz-ArruzaI. PellettF. ChandranV. CookR.J. GladmanD.D. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.Arthritis Care Res. (Hoboken)201567684284710.1002/acr.2252925469741
     [Google Scholar]
  85. Araujoe.g. FinzelS. EnglbrechtM. SchreiberD.A. FaustiniF. HueberA. NasK. RechJ. SchettG. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.Ann. Rheum. Dis.201574465566010.1136/annrheumdis‑2013‑20422924336010
     [Google Scholar]
  86. CoatesL.C. PillaiS.G. TahirH. ValterI. ChandranV. KamedaH. OkadaM. KerrL. AlvesD. ParkS.Y. AdamsD.H. GalloG. HuffordM.M. HojnikM. MeaseP.J. KavanaughA. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study.Arthritis Rheumatol.20217391663167210.1002/art.4171633682378
     [Google Scholar]
  87. HuynhD.H. BoydT.A. EtzelC.J. CoxV. KremerJ. MeaseP. KavanaughA. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.RMD Open201731e00039510.1136/rmdopen‑2016‑00039528123783
     [Google Scholar]
  88. MichielsensC.A.J. den BroederN. van den HoogenF.H.J. MahlerE.A.M. TeerenstraS. van der HeijdeD. VerhoefL.M. den BroederA.A. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.Ann. Rheum. Dis.202281101392139910.1136/annrheumdis‑2022‑22226035701155
     [Google Scholar]
  89. NagyG. RoodenrijsN.M.T. WelsingP.M.J. KedvesM. HamarA. van der GoesM.C. KentA. BakkersM. BlaasE. SenoltL. SzekaneczZ. ChoyE. DougadosM. JacobsJ.W.G. GeenenR. BijlsmaH.W.J. ZinkA. AletahaD. SchoneveldL. van RielP. GutermannL. PriorY. NikiphorouE. FerraccioliG. SchettG. HyrichK.L. Mueller-LadnerU. BuchM.H. McInnesI.B. van der HeijdeD. van LaarJ.M. Eular definition of difficult-to-treat rheumatoid arthritis.Ann. Rheum. Dis.2021801313510.1136/annrheumdis‑2020‑21734433004335
     [Google Scholar]
  90. GriffithsC.E.M. ThaçiD. GerdesS. ArenbergerP. PulkaG. KingoK. WeglowskaJ. HattebuhrN. PoetzlJ. WoehlingH. WuerthG. AfonsoM. The egality study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.Br. J. Dermatol.2017176492893810.1111/bjd.1515227787890
     [Google Scholar]
  91. PappK. BachelezH. CostanzoA. FoleyP. GooderhamM. KaurP. NarbuttJ. PhilippS. SpelmanL. WeglowskaJ. ZhangN. StroberB. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.J. Am. Acad. Dermatol.20177661093110210.1016/j.jaad.2016.12.01428291552
     [Google Scholar]
/content/journals/crr/10.2174/0115733971339350240830104424
Loading
Updates on Recent Advances in the Therapy of Adult Psoriatic Disease
Curr. Rheumatol. Rev. 21, 495 (2025); https://doi.org/10.2174/0115733971339350240830104424
/content/journals/crr/10.2174/0115733971339350240830104424
/content/journals/crr/10.2174/0115733971339350240830104424
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): inflammatory disease; Psoriatic  arthritis;  advances;  axial  disease;  disease-modifying  anti-rheumatic  drugs;  psoriasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test